Drug Trial News

RSS

QUANTUM trial tests immune-targeting approach for primary plasma cell leukemia

The Alliance for Clinical Trials in Oncology today announced the activation of The QUANTUM Trial (Alliance A062401), a clinical study designed to test a novel, immune-targeting approach for patients newly diagnosed with primary plasma cell leukemia (PCL).

30 Jul 2026

Dual immunotherapy with neoadjuvant chemotherapy shows encouraging activity in ERBB2-negative breast cancer

A combination of two immunotherapy drugs showed encouraging activity when added to standard chemotherapy given prior to surgery for patients with high-risk, early-stage HER2-negative breast cancer, according to phase 2 clinical trial results from the ongoing I-SPY2 clinical trial platform.

30 Jul 2026

Perilla oil improves blood flow and reduces inflammation in healthy smokers

Cardiovascular disease (CVD) is among the leading causes of death worldwide. In South Korea, it is the second leading cause of death, and its incidence has continued to rise in recent years.

30 Jul 2026

Psilocybin trial shows striking remission rates for veterans with PTSD

The first U.S. clinical trial of psilocybin-assisted therapy in veterans with PTSD who got no relief from conventional treatments has established that the protocol is safe, causing no serious adverse events or increases in suicidal thinking or behavior.

30 Jul 2026

Omalizumab beats multiallergen oral immunotherapy in multifood allergy trial

Omalizumab demonstrates higher treatment success for multifood allergies compared to oral immunotherapy, with fewer adverse events impacting patient retention.

30 Jul 2026

Combination therapy improves progression-free survival in dMMR/MSI-H metastatic colorectal cancer

Patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer experienced a 58% reduction in the risk of disease progression or death when treated with atezolizumab plus modified FOLFOX6 and bevacizumab compared with atezolizumab alone, according to results from the NRG-GI004/SWOG S1610 COMMIT trial published recently in the Journal of Clinical Oncology.

29 Jul 2026

Once-weekly oral tablet proves highly effective for HIV care

An international clinical trial led by researchers including Professor Chloe Orkin of Queen Mary University of London has shown that a once-weekly oral treatment for HIV is as effective as one of today's leading daily therapies, offering the potential for a new treatment option that could reduce the burden of lifelong daily pill-taking.

29 Jul 2026

Deramiocel cell therapy slows muscle and heart damage in advanced DMD

A cell therapy called deramiocel could slow muscle weakening in boys and young men with advanced Duchenne muscular dystrophy (DMD), and may also slow heart damage in those who already have heart muscle disease, a phase 3 clinical trial published in The Lancet has found.

29 Jul 2026

Oral semaglutide reduces heavy drinking in adults with alcohol use disorder

A clinical trial led by researchers at CU Anschutz has found that oral semaglutide, a medication widely used for diabetes and weight loss, reduces heavy drinking in adults with Alcohol Use Disorder (AUD).

29 Jul 2026

THC and CBD combination rapidly reduces advanced dementia agitation

A combination of CBD and THC rapidly and significantly reduces agitation in hospice-eligible people with dementia, suggest topline results from the Phase 2 LiBBY (Life's End Benefits of cannaBidiol and tetrahYdrocannabinol) clinical trial.

28 Jul 2026

Remdesivir protects kidney and heart health in transplant recipients

Adults with kidney transplants who were treated for COVID-19 with the antiviral remdesivir within a week of COVID-19 diagnosis and who received at least three consecutive days of therapy were less likely than kidney transplant recipients who did not receive the antiviral to experience cardiovascular or kidney problems up to a year later, according to findings from a target trial emulation study that published in JAMA Network Open.

28 Jul 2026

Major clinical trial aims to transform the prevention of recurrent urinary tract infections

European-funded consortium brings together researchers from 13 countries to evaluate bacteriophage therapy as a potential alternative to antibiotics for recurrent urinary tract infections.

28 Jul 2026

Casdatifan demonstrates durable responses in advanced kidney cancer trial

A new multi-center clinical study is shedding light on a potential new approach for patients with advanced kidney cancer, offering measurable clinical responses alongside a clearer view into how the disease operates beneath the surface.

27 Jul 2026

Phase 3 clinical trial enrolls first platinum-resistant ovarian cancer patient

The GOG Foundation, Inc. is proud to announce the enrollment of the first patient in GOG-3132/BEHOLD-Ovarian01 (NCT07286266), a global Phase 3 clinical trial titled A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants with Platinum-resistant Ovarian Cancer.

27 Jul 2026

Oral antibiotics safely shorten hospital stays for children with pneumonia

Children hospitalized with severe pneumonia can safely switch from injectable to oral antibiotics once they begin to recover, allowing many to return home sooner and complete treatment outside hospital.

23 Jul 2026

Oral drug avatrombopag reduces chemotherapy treatment delays, trial finds

In a phase 2 trial of patients with gastrointestinal cancers, avatrombopag helped 70% of those receiving chemotherapy to stay on treatment schedule, compared with 17% receiving placebo.

20 Jul 2026

Experimental drug shows promise against NRAS-driven melanoma

A research team from Huntsman Cancer Institute at the University of Utah (the U) reports that a groundbreaking pathway-targeted therapy could be an effective treatment for certain melanoma patients and fill an unmet clinical need for patients with advanced disease.

16 Jul 2026

Long-term lenalidomide maintenance shows no survival advantage in multiple myeloma

For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance has long been standard care despite limited evidence to guide the optimal duration of treatment.

16 Jul 2026

Extended myeloma maintenance therapy shows no additional survival benefit

A major national cooperative group clinical trial led by Mayo Clinic researchers found that continuing maintenance therapy with lenalidomide beyond two years after initial treatment for standard-risk multiple myeloma did not improve overall survival compared with stopping treatment after two years.

15 Jul 2026